|
|
 |
|
Viewing report
|
|
|
|
Cytomegalovirus (CMV) Retinitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, March 2011, Pages: 51
Cytomegalovirus (CMV) Retinitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Cytomegalovirus (CMV) Retinitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global CMV retinitis market and pipeline.The report identifies the key trends shaping and driving the global CMV Retinitis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CMV Retinitis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData has estimated the global CMV retinitis market to be valued at $525m in 2010. It is expected to decrease to $400m with a negative Compound Annual Growth Rate (CAGR) of 3.8% by 2017. There is high unmet need in the current CMV Retinitis market in terms of both safety and efficacy profile for overall therapy including induction and maintenance. No new product is expected till 2017 in the market. All products in pipeline are for prophylaxis of CMV infection overall and not for treatment of CMV retinitis.
Scope
The report provides information on the key drivers and challenges of the CMV retinitis market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) CMV retinitis market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. There are no late stage products as pipeline candidates. The pipeline consists of all novel molecules that are prophylactic vaccines for the prevention of CMV infection on the whole in healthy individuals.
- Analysis of the current and future competition in the global CMV retinitis market. Key market player covered is Sanofi Pasteur
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the CMV Retinitis Therapeuticsmarket.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global CMV Retinitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global CMV Retinitis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global CMV Retinitis market landscape? – Identify, understand and capitalize.
|
|
|
|
